Tuesday July 28, 2:02 pm Eastern Time
Company Press Release
SOURCE: Paracelsian Inc.
Paracelsian Announces Actions on Andrographalide and BioFIT Patent
Applications
ITHACA, N.Y., July 28 /PRNewswire/ -- Paracelsian, Inc. (Nasdaq: PRLN - news; paracelsian.com)
announced today that it has applied to change the status of its pending patent application for the medicinal uses
of Andrographalide, an extract of the herb Andrographis paniculata, in order to speed the approval process. The
company also announced the filing of the second in a series of patent applications related to its BioFIT(TM)
''functional'' quality assurance program for herbal products.
In the first action, Paracelsian is filing a ''Petition to Make Special'' for its patent application related to methods of
using andrographolide and related extracts of Andrographis paniculata for treating cancer, HIV, angiogenesis,
Alzheimer's and hepatitis, and depression. Andrographis paniculata is one of over 2,700 herbal extracts in
Paracelsian's library of Traditional Chinese Medicines.
The ''Petition to Make Special'' is a procedure within the patent office that provides for quicker examination of
applications related to AIDS treatments. Paracelsian expects that this will greatly decrease the examination period
for its patent applications related to andrographolide, helping to make its potential medical benefits available to
those in need more quickly.
In the second action, Paracelsian filed a U.S. patent application for a novel ''in vitro'' bioassay to be used in
establishing and confirming the biological activity of Saw Palmetto, a popular herb sold with claims for the
maintenance of a healthy prostate gland. It is the second in a series of patent applications related to Paracelsian's
BioFIT(TM) ''functional quality assurance program for herbal products. The company recently announced an
agreement with R.P. Scherer North America to market and distribute herbal products utilizing the BioFIT
technology.
''These patent actions clearly demonstrate our intent to move forward aggressively with our strategy of fully
developing and commercializing our current intellectual properties, as well add expanding their number of scope,''
said Bernie Landes, Paracelsian's President and CEO. ''We believe that Andrographalide and other related
extracts of Andrographis paniculata have great potential to benefit many people with life threatening, and
debilitating illnesses and look forward to the possibility of being able to help them,'' he added.
Paracelsian is a unique biotechnology company whose business centers on the development and application of
functional bioassays. These assays are used for Quality Assurance of herbs, botanicals and other dietary
supplements, in the development of dietary supplement, OTC and pharmaceutical products, and in monitoring
environmental toxins and identifying carcinogens.
Notice: This news release and oral statements made from time to time by Company representatives concerning
the same subject matter may contain so-called ''forward-looking statements'.'' These statements can be identified
by introductory words such as ''expects','' ''plans','' ''will,'' ''estimates,'' ''forecasts,'' ''projects''' or words of
similar meaning.
Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not
limited to, the results of research and development efforts, the effect of regulation by the United States Food and
Drug Administration and other agencies, the impact of competitive products, product development
commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed
with the Securities and Exchange Commission.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue
reliance on such statements.
SOURCE: Paracelsian Inc. |
